December 2025

Why Disney is embedding generative AI into its operating model

For a company built on intellectual property, scale creates a familiar tension. Disney needs to produce and distribute content across many formats and audiences, while keeping tight control over rights, safety, and brand consistency. Generative AI promises speed and flexibility, but unmanaged use risks creating legal, creative, and operational drag. Disney’s agreement with OpenAI shows

Why Disney is embedding generative AI into its operating model Read More »

Arm and the future of AI at the edge

Arm Holdings has positioned itself at the centre of AI transformation. In a wide-ranging podcast interview, Vince Jesaitis, head of global government affairs at Arm, offered enterprise decision-makers look into the company’s international strategy, the evolution of AI as the company sees it, and what lies ahead for the industry. From cloud to edge Arm

Arm and the future of AI at the edge Read More »

Zara’s use of AI shows how retail workflows are quietly changing

Zara is testing how far generative AI can be pushed into everyday retail operations, starting with a part of the business that rarely gets attention in technology discussions: product imagery. Recent reporting shows the retailer using AI to generate new images of real models wearing different outfits, based on existing photoshoots. Models remain involved in

Zara’s use of AI shows how retail workflows are quietly changing Read More »

AI in Human Resources: the real operational impact

Human Resources is an area in many organisations where AI can have significant operational impact. The technology is now being embedded into day-to-day operations, in activities like answering employees’ questions and supporting training. The clearest impact appears where organisations can measure the tech’s outcomes, typically in time saved and the numbers of queries successfully resolved.

AI in Human Resources: the real operational impact Read More »

AstraZeneca leads big pharma’s AI clinical trials revolution with real-world patient impact

Big Pharma’s AI race extends across drug discovery, development, and clinical trials—but AstraZeneca has distinguished itself by deploying AI clinical trials technology at an unprecedented public health scale.  While competitors optimise internal R&D pipelines, AstraZeneca’s AI is already embedded in national healthcare systems, screening hundreds of thousands of patients and demonstrating what happens when AI

AstraZeneca leads big pharma’s AI clinical trials revolution with real-world patient impact Read More »